BeStock  
Stocks › Biotechnology › MIRM

Mirum Pharmaceuticals MIRM

US equityMarket cap rank #1818Biotechnology
$96.13 +$0.62 (+0.65%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $96.13 0.00%
Open$94.50
Prev close$95.51
Day range$94.10 – $98.39
Volume1.06M
Market cap$6.28B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$185.72M+39.6% YoY
Operating profit-$46.25M-1,876.6% YoY
Net profit-$40.77M-1,503.3% YoY
Diluted EPS-$0.87-1,840.0% YoY
Free cash flow-$5.62M-114.2% YoY
Operating cash flow-$4.31M

Revenue, last 8 quarters

$99.4MDec '24$111.6MMar '25$127.8MJun '25$133.0MSep '25$148.9MDec '25$159.9MMar '26$176.2MJun '26$185.7MSep '26

Net profit, last 8 quarters

$-23.8MDec '24$-14.7MMar '25$-5.9MJun '25$2.9MSep '25$-5.7MDec '25$-790.2MMar '26$-67.2MJun '26$-40.8MSep '26

Diluted EPS by quarter

-0.49Dec '24-0.30Mar '25-0.12Jun '250.05Sep '25-0.11Dec '25-13.43Mar '26-1.06Jun '26-0.87Sep '26

Free cash flow by quarter

$-5.1MDec '24$-2.0MMar '25$11.9MJun '25$39.5MSep '25$5.5MDec '25$-239.4MMar '26$-69.3MJun '26$-5.6MSep '26

Annual revenue

$0.0FY20$19.1MFY21$77.1MFY22$186.4MFY23$336.9MFY24$521.3MFY25

Profitability & balance sheet

Gross margin81.7%
Operating margin-21.6%
Net margin-134.8%
Return on equity-760.0%
Return on assets-99.8%
Return on invested capital-139.4%
Current ratio2.07
Liabilities / assets105.3%
Cash & investments$373.69M
Total debt$740.97M
Net cash (debt)-$367.28M

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Livmarli$133.45M 71.9%
  • Bile Acid Medicines$52.27M 28.1%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $185.72M $176.24M $159.88M $521.31M $148.93M
Total Operating Revenue $185.72M $176.24M $159.88M $521.31M $148.93M
Cost of Revenue $35.17M $30.35M $28.81M $100.24M $28.26M
Gross Profit $150.55M $145.90M $131.08M $421.07M $120.67M
Operating Expense $196.80M $172.00M $194.24M $443.21M $130.24M
Selling and Admin Expenses $88.86M $81.47M $96.33M $257.03M $74.13M
Research & Development $107.93M $90.53M $97.91M $186.18M $56.11M
Operating Profit -$46.25M -$26.10M -$63.16M -$22.14M -$9.57M
Net Non-Operating Interest Income (Expense) $3.08M $1.23M -$215,000.00 -$1.66M -$178,000.00
Non-Operating Interest Income $4.69M $3.85M $3.40M $12.73M $3.42M
Non-Operating Interest Expense $1.61M $2.62M $3.62M $14.39M $3.60M
Other Income (Expense) $2.94M -$40.67M -$726.30M $2.37M $4.78M
Special Income (Charges) -$13.50M -$16.44M -$726.30M $0.00 $5.00M
-Less:Other Special Charges $13.50M $16.44M $726.30M – –
Other Non-Operating Income (Expenses) $16.44M -$24.23M – $2.37M -$218,000.00
Pretax Profit -$40.23M -$65.54M -$789.68M -$21.43M -$4.96M
Tax $538,000.00 $1.69M $475,000.00 $1.94M $767,000.00
Net Profit -$40.77M -$67.23M -$790.16M -$23.36M -$5.73M
Profit from Continuing Operations -$40.77M -$67.23M -$790.16M -$23.36M -$5.73M
Net Income to Parent Company -$40.77M -$67.23M -$790.16M -$23.36M -$5.73M
Net Income to Common Stockholders -$40.77M -$67.23M -$790.16M -$23.36M -$5.73M
Basic EPS -$0.62 -$1.06 -$13.43 -$0.47 -$0.11
Diluted EPS -$0.87 -$1.06 -$13.43 -$0.47 -$0.11

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.03B $1.04B $890.92M $842.81M $842.81M
Total Current Assets $586.63M $636.31M $569.44M $549.68M $549.68M
Cash and Cash Equivalents & Short-Term Investments $373.69M $438.29M $386.26M $383.33M $383.33M
-Cash and Cash Equivalents $243.19M $330.73M $324.91M $296.68M $296.68M
-Short Term Investments $130.50M $107.56M $61.35M $86.64M $86.64M
Receivables $156.35M $145.36M $133.11M $123.33M $123.33M
-Accounts Receivable $156.35M $145.36M $133.11M $123.33M $123.33M
Inventory $25.49M $25.77M $25.52M $24.89M $24.89M
Other Current Assets $31.11M $26.89M $24.55M $18.14M $18.14M
Total Non-Current Assets $439.98M $408.67M $321.48M $293.13M $293.13M
Net PPE $14.61M $14.28M $15.06M $10.60M $10.60M
-Gross PPE $14.61M $14.28M $15.06M $10.60M $10.60M
Investments and Advances $126.77M $123.03M $34.35M $8.11M $8.11M
Goodwill and Other Intangible Assets $275.65M $247.39M $254.15M $260.92M $260.92M
-Other Intangible Assets $275.65M $247.39M $254.15M $260.92M $260.92M
Other Non-Current Assets $22.96M $23.98M $17.91M $13.50M $13.50M
Total Liabilities $1.08B $1.06B $648.42M $528.12M $528.12M
Total Current Liabilities $283.08M $222.79M $272.82M $205.80M $205.80M
Payables $33.83M $39.63M $74.62M $25.82M $25.82M
-Accounts Payable $13.65M $23.43M $59.40M $9.61M $9.61M
-Other Payable $20.18M $16.20M $15.22M $16.21M $16.21M
Current Accrued Expenses $181.33M $127.56M $134.62M $130.56M $130.56M
Short-Term Debt and Capital Lease Obligation $2.60M $2.41M $2.35M $2.14M $2.14M
-Current Capital Lease Obligation $2.60M $2.41M $2.35M $2.14M $2.14M
Other Current Liabilities $24.80M $24.80M $25.80M – –
Total Non-Current Liabilities $797.72M $832.62M $375.60M $322.32M $322.32M
Long Term Debt and Capital Lease Obligation $740.97M $760.54M $321.43M $317.31M $317.31M
-Long Term Debt $731.25M $750.08M $310.25M $309.80M $309.80M
-Long Term Capital Lease Obligation $9.72M $10.47M $11.18M $7.52M $7.52M
Other Non-Current Liabilities $56.75M $72.07M $54.17M $5.01M $5.01M
Total Equity -$54.19M -$10.42M $242.49M $314.69M $314.69M
Stockholders' Equity -$54.19M -$10.42M $242.49M $314.69M $314.69M
Capital Stock $7,000.00 $6,000.00 $6,000.00 $5,000.00 $5,000.00
-Common Stock $7,000.00 $6,000.00 $6,000.00 $5,000.00 $5,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.51B $1.52B $1.70B $981.88M $981.88M
Retained Earnings -$1.57B -$1.52B -$1.46B -$667.54M -$667.54M
Gains/Losses Not Affecting Retained Earnings -$2.06M -$674,000.00 -$28,000.00 $351,000.00 $351,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$4.31M -$44.25M -$228.76M $55.83M $6.07M
Net cash flow from continuing operations -$4.31M -$44.25M -$228.76M $55.83M $6.07M
Net Income from Continuing Operations -$40.77M -$67.23M -$790.16M -$23.36M -$5.73M
Gain/Loss from Continuing Operations -$170,000.00 $896,000.00 $1.10M -$1.72M $193,000.00
Depreciation & Depletion & Amortization $6.89M $6.94M $6.87M $24.24M $6.07M
Other Non-Cash Items -$15.35M $24.79M -$272,000.00 $2.07M $511,000.00
Change in Working Capital $10.97M -$40.22M $102.22M -$19.72M -$14.01M
-Change in Receivables -$13.06M -$13.74M -$12.89M -$48.06M -$19.01M
-Change in Inventory -$889,000.00 $395,000.00 -$1.92M -$8.45M -$2.28M
-Change in Prepaid Assets -$4.31M -$1.08M -$6.63M -$5.76M $5.99M
-Change in Payables and Accrued Expense $29.19M -$19.06M $57.24M $50.10M $3.44M
-Change in Other Current Assets $546,000.00 -$5.84M -$4.80M -$5.66M -$1.64M
-Change in Other Current Liabilities -$507,000.00 -$891,000.00 $71.21M -$1.90M -$513,000.00
Net cash flow from investing -$28.87M -$159.99M -$11.57M -$23.95M $1.01M
Net Cash Flow from Continuing Investing Activities -$28.87M -$159.99M -$11.57M -$23.95M $1.01M
Net PPE Purchase and Sale -$1.31M -$23,000.00 -$664,000.00 -$954,000.00 -$600,000.00
Net Intangibles Purchase and Sale $0.00 -$25.00M -$10.00M $0.00 $0.00
Net Investment Purchase and Sale -$27.56M -$134.97M -$905,000.00 -$23.00M $1.61M
Financing Cash Flow -$54.34M $211.44M $270.08M $40.14M $9.00M
Net Cash Flow from Continuing Financing Activities -$54.34M $211.44M $270.08M $40.14M $9.00M
Net Issuance Payments Of Debt -$62.10M – – $0.00 $0.00
Net Common Stock Issuance $0.00 $0.00 $259.95M $0.00 $0.00
Proceeds from Stock Option Exercised $7.76M $13.37M $10.13M $40.14M $9.00M
Ending Cash Balance $244.92M $332.46M $326.64M $298.17M $298.17M
Net Change in Cash -$87.52M $7.20M $29.75M $72.02M $16.07M
Beginning Cash Balance $332.46M $326.64M $298.17M $222.93M $282.50M
Effect of Exchange Rate Changes -$17,000.00 -$1.37M -$1.27M $3.22M -$408,000.00
Free Cash Flow -$5.62M -$69.28M -$239.43M $54.87M $5.47M
Net Business Purchase and Sale – – – $0.00 –

Discussion

No comments yet — be the first to weigh in on MIRM.

Sign in to join the discussion.

Scroll to Top